Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Gut

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Overall survival ‐ Additive comparisons · people with advanced gastric cancer

Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.88 [0.76, 1.03]
3 studies · 500 participants
Low

Overall survival ‐ Additive comparisons · people with advanced gastric cancer

Docetaxel probably leads to lower overall survival ‐ Additive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.8 [0.71, 0.91]
4 studies · 1466 participants
Moderate